Skip to main content
Smart Investors Daily
Charles River Laboratories International, Inc. logo

NYSE · CRL

Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

$327.93

Down-$5.32 (-1.60%)

Updated Nov 20, 2026, 2:28 AM

SID Score

6.5/10

Composite research score

Smart Money

54/100

Neutral

Market cap
9.57B
P/E ratio
-137.99
Dividend yield
0.00%
52-week range
$146.20 – $379.63
Volume
495.1K
Avg. volume
1.03M

Price performance · CRL

CRL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

CRL closed at $327.93 after 21 trading sessions, down 3.45% for the selected period.

Last close
$327.93
Period change
-3.45%
Period low
$313.02
Period high
$376.10
Daily close
View OHLC price history
CRL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$337.20$343.57$326.53$327.93495.1K
Nov 18, 2026$332.15$338.53$330.405$333.25516.51K
Nov 17, 2026$333.26$341.385$331.255$332.16697.55K
Nov 16, 2026$334.13$338.20$328.68$335.52693.84K
Nov 13, 2026$342.18$342.58$333.04$337.97838.32K
Nov 12, 2026$335.66$342.83$326.29$340.81902.12K
Nov 11, 2026$347.38$356.00$342.25$342.69836.56K
Nov 10, 2026$350.44$352.50$342.39$345.80822.08K
Nov 9, 2026$343.44$358.765$342.00$353.34943.31K
Nov 6, 2026$318.73$339.97$316.61$337.521.06M
Nov 5, 2026$330.14$330.75$311.68$313.021.66M
Nov 4, 2026$349.90$354.99$325.35$326.291.73M
Nov 3, 2026$339.88$356.35$338.55$351.871.6M
Nov 2, 2026$368.42$369.61$337.37$338.541.62M
Oct 30, 2026$372.99$374.56$351.98$359.411.5M
Oct 29, 2026$375.00$379.63$368.63$376.10887.34K
Oct 28, 2026$360.01$378.23$360.01$373.981.3M
Oct 27, 2026$351.95$359.89$351.95$358.841.16M
Oct 26, 2026$347.59$357.77$345.89$357.271.18M
Oct 23, 2026$337.78$347.195$332.17$345.37822.3K
Oct 22, 2026$341.43$351.21$337.78$339.662.66M

Latest CRL news

The latest Smart Investors Daily articles mentioning CRL.

CRL research

Overview

Company profile and research snapshot.

Company profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$191.50
Implied upside
—
Analysts
22
CRL recent ratings
DateFirmRatingTarget
Nov 5, 2026Evercore ISI GroupOutperform—
Nov 5, 2026UBSBuy—
Nov 5, 2026BarclaysOverweight—
Nov 5, 2026RBC CapitalOutperform—
Oct 13, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

Charles River Laboratories International Inc. (NYSE:CRL) on Monday agreed to acquire the bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations of Frontage Holdings Corporation in Exton, Pennsylvania, for approximately $470 million in cash. The transaction also includes up to $75 million in performance-based earnout payments, positioning Charles River to capture expanding biopharmaceutical demand. Expanding Clinical Bioanalysis Capabilities And Balancing Laboratory Portfolio The

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.